8.1 Implantable Devices: ICD and CRT Indications, Titration, and Screening

Cardiac Implantable Electronic Devices (CIEDs) in Heart Failure

Sudden cardiac death (SCD) secondary to ventricular tachyarrhythmias (ventricular tachycardia [VT] and ventricular fibrillation [VF]) has historically accounted for up to about half of deaths in heart failure, with the highest proportion in patients with mild-to-moderate symptoms (NYHA Class II–III); that share has fallen with modern GDMT. Concurrently, electromechanical dyssynchrony—manifested by intraventricular conduction delays such as Left Bundle Branch Block (LBBB)—impairs left ventricular systolic performance, increases wall stress, exacerbates functional mitral regurgitation, and accelerates adverse cardiac remodeling. Contemporary heart failure management integrates cardiac implantable electronic devices (CIEDs), specifically Implantable Cardioverter-Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT), to prevent sudden arrhythmic death and restore mechanical synchrony.

---

Implantable Cardioverter-Defibrillator (ICD) Therapy

An ICD continuously monitors intracardiac electrograms, detects malignant ventricular tachyarrhythmias, and delivers tiered electrical therapy: painless anti-tachycardia pacing (ATP) to terminate monomorphic VT, low-energy cardioversion, and high-energy defibrillation shocks (typically 30–40 Joules) for rapid VT or VF. Patient selection is categorized into primary prevention (patients at high risk who have not yet experienced a sustained ventricular arrhythmia or cardiac arrest) and secondary prevention (survivors of sustained ventricular arrhythmias or aborted sudden cardiac death).

                  ┌────────────────────────────────────────────────────────┐
                  │           ICD INDICATIONS IN HEART FAILURE             │
                  └───────────┬────────────────────────────────┬───────────┘
                              │                                │
                              ▼                                ▼
               ┌──────────────────────────────┐ ┌──────────────────────────────┐
               │      Primary Prevention      │ │     Secondary Prevention     │
               │  • LVEF ≤35%, NYHA II–III    │ │  • Survived VF arrest OR     │
               │  • Optimal GDMT ≥90 days     │ │    sustained hemodynamically │
               │  • Ischemic: ≥40 days post-MI│ │    unstable VT               │
               │  • Life expectancy >1 year   │ │  • Absence of reversible cause│
               │  • Class I if LVEF ≤30% post-│ │  • Class 1 recommendation    │
               │    MI ≥40 days (MADIT-II)    │ │                              │
               └──────────────────────────────┘ └──────────────────────────────┘

Primary Prevention Indications and Landmark Trials

Guidelines establish clear criteria for primary prevention ICD placement:

1. Ischemic Cardiomyopathy:
   • LVEF ≤35%, NYHA Class II or III symptoms on chronic optimal guideline-directed medical therapy (GDMT), at least 40 days post-myocardial infarction (MI), at least 90 days post-revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]), and a reasonable expectation of meaningful survival with good functional status for greater than 1 year (Class 1, Level of Evidence A).
   • LVEF ≤30%, NYHA Class I symptoms on optimal GDMT, ischemic cardiomyopathy, at least 40 days post-MI, and life expectancy >1 year (Class 1, Level of Evidence A; based on the MADIT-II trial, which demonstrated a 31% relative risk reduction in all-cause mortality).
2. Non-Ischemic Cardiomyopathy (DCM):
   • LVEF ≤35%, NYHA Class II or III symptoms, receiving at least 90 days of optimal GDMT, and a reasonable expectation of meaningful survival with good functional status for greater than 1 year (Class 1, Level of Evidence A; supported by the SCD-HeFT trial, which demonstrated a 23% relative risk reduction in all-cause mortality).

The Rationale for Mandatory Waiting Periods

The Certified Heart Failure Nurse (CHFN) must master the physiological and clinical rationales behind the mandatory waiting periods prior to ICD implantation:

• The 40-Day Post-MI Rule: In the DINAMIT and IRIS trials, implanting an ICD within the first 40 days after an acute MI reduced arrhythmic death but did not reduce all-cause mortality. During this early post-infarction phase, excess mortality was driven by recurrent reinfarction, acute mechanical complications, and progressive pump failure that an ICD cannot prevent. Furthermore, stunning and hibernating myocardium may recover substantial systolic function following successful reperfusion.
• The 90-Day GDMT / Revascularization Rule: Initiation and uptitration of foundational GDMT (ARNI, evidence-based beta-blockers, MRAs, SGLT2 inhibitors) and myocardial revascularization frequently induce profound reverse left ventricular remodeling. A substantial proportion of patients improve their LVEF above 35% within 3 to 6 months of optimized therapy, thereby eliminating their indication for an ICD and sparing them lifetime risks of lead complications, device infections, and inappropriate shocks.
• Wearable Cardioverter-Defibrillator (WCD / LifeVest): For high-risk patients during the mandatory 40-day post-MI or 90-day GDMT titration waiting window (e.g., severe LV dysfunction with LVEF <25% or frequent nonsustained VT), a wearable cardioverter-defibrillator may be prescribed as a temporary bridge to permanent ICD decision-making. Use is individualized: in the VEST trial, the WCD did not significantly reduce arrhythmic death by intention to treat, and benefit depended on consistent wear.

Secondary Prevention Indications

Secondary prevention ICD implantation carries a Class 1 recommendation for patients who:

1. Have survived an episode of cardiac arrest caused by ventricular fibrillation (VF) or
2. Have experienced sustained, hemodynamically unstable ventricular tachycardia (VT), either spontaneous or induced during an electrophysiology study.

[!IMPORTANT] Reversible Causes Caveat: Secondary prevention ICD is indicated only in the absence of a completely reversible or transient cause. If ventricular fibrillation occurs within the first 48 hours of an acute ST-elevation myocardial infarction (primary ischemic arrhythmia), or is provoked by transient, reversible severe electrolyte derangements (e.g., profound hypokalemia K+ <2.5 mEq/L) or toxic drug-induced proarrhythmia (e.g., QT-prolonging agent inducing Torsades de Pointes), the underlying etiology is corrected, and an ICD is not indicated.

---

Cardiac Resynchronization Therapy (CRT)

In approximately one-third of patients with advanced HFrEF, conduction delay across the specialized His-Purkinje system—most frequently manifesting as Left Bundle Branch Block (LBBB)—causes dyssynchronous ventricular contraction. Depolarization propagates slowly across working myocytes from the right ventricle across the septum to the left ventricular free wall. The septum contracts early against an un-depolarized, compliant LV free wall, while the lateral LV wall contracts late against high wall tension, impairing stroke volume, reducing peak LV rate of pressure rise (dP/dt), worsening functional mitral regurgitation, and promoting asymmetric myocyte hypertrophy.

Cardiac Resynchronization Therapy (also termed biventricular pacing) utilizes a triple-lead system:

1. Right Atrial (RA) Lead: Senses and paces atrial activity.
2. Right Ventricular (RV) Lead: Positioned in the RV apex or septum for sensing, pacing, and defibrillation.
3. Left Ventricular (LV) Lead: Threaded transvenously through the coronary sinus into an epicardial posterolateral cardiac vein, directly pacing the delayed lateral wall of the left ventricle.

Simultaneous or sequentially timed biventricular depolarization restores coordinated septal and lateral wall contraction, prolongs diastolic filling time, minimizes mitral regurgitation, improves LVEF by 5% to 10%, and reduces all-cause mortality and heart failure hospitalizations (proven in landmark trials COMPANION, CARE-HF, and MADIT-CRT).

                    ELECTROMECHANICAL DYSSYNCHRONY AND CRT

     Native Conduction (LBBB)                      Biventricular Pacing (CRT)
   ┌───────────────────────────┐                 ┌───────────────────────────┐
   │ • Septum contracts early  │                 │ • Simultaneous RV and LV  │
   │ • Lateral LV wall delayed │   CRT Delivery  │   myocardial stimulation  │
   │ • Septal rocking / bounce ├────────────────►│ • Coordinated contraction │
   │ • Severe mitral regurg    │                 │ • ↑ dP/dt & Stroke Volume │
   │ • Inefficient hemodynamics│                 │ • Reverse LV Remodeling   │
   └───────────────────────────┘                 └───────────────────────────┘

Guideline Recommendations for CRT Initiation

CRT-D vs. CRT-P: Selecting the Device

• CRT-D (Defibrillator): Combines biventricular resynchronization pacing with full ICD functionality (ATP and defibrillation shocks). Preferred in the vast majority of ambulatory heart failure patients with LVEF ≤35% who meet primary or secondary ICD criteria and have life expectancy >1 year.
• CRT-P (Pacemaker only): Provides biventricular resynchronization pacing and anti-bradycardia pacing without shock capability. Preferred in patients with advanced age, severe non-cardiac frailty, bedbound end-stage comorbidities, terminal malignancies, or those whose personal goals of care prioritize symptom relief while explicitly declining sudden death prevention.

The Critical >98% Biventricular Pacing Rule

Unlike standard pacemakers that pace only on demand when native conduction fails, CRT must pace continuously to achieve mechanical resynchronization. Every non-paced native beat or fusion beat represents dyssynchrony.

• Mandatory Pacing Target: Clinical trials demonstrate that reverse LV remodeling, functional improvement, and mortality reduction occur only when the biventricular pacing percentage exceeds 98% (ideally 99% to 100%). Pacing percentages between 90% and 95% are clinically inadequate and associated with elevated mortality and recurrent hospitalizations.
• Causes of Inadequate Biventricular Capture:
  1. Atrial Fibrillation with Rapid Ventricular Response (AF with RVR): Intrinsic fibrillatory impulses conduct rapidly through the AV node, depolarizing the ventricles natively and inhibiting the pacemaker output. Management involves aggressive rate control with beta-blockers, amiodarone, or catheter AV node ablation ("pace and ablate" strategy) to guarantee 100% pacing capture.
  2. Frequent Premature Ventricular Contractions (PVCs): High PVC burden (>10% to 15% of total beats) prevents biventricular capture during ectopic beats and the post-extrasystolic pause. Management includes antiarrhythmic therapy or catheter ablation of the PVC focus.
  3. Suboptimal Programming: Inappropriate atrioventricular (AV) delay (causing pseudofusion or native conduction breakthrough) or ventriculoventricular (VV) timing offsets. Management involves device interrogation and echocardiographic or electrogram-guided optimization.
  4. Lead Complications: LV lead dislodgement, elevated pacing thresholds, or phrenic nerve stimulation (causing involuntary diaphragmatic twitching). Management requires electronic vector reprogramming (electronic repositioning via multipolar LV leads) or surgical lead revision.

---

Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD)

Traditional transvenous ICDs carry long-term risks related to intravascular leads, including pneumothorax, subclavian vein thrombosis/stenosis, tricuspid valve laceration/regurgitation, lead fracture, and endovascular lead infections (endocarditis). The Subcutaneous ICD (S-ICD) was developed to eliminate these intravascular and intracardiac complications.

                     S-ICD SYSTEM ANATOMY AND CAPABILITIES

                 ┌──────────────────────────────────────────────┐
                 │              Pulse Generator                 │
                 │   • Implanted in left mid-axillary space     │
                 │   • 6th intercostal space over latissimus    │
                 └──────────────────────┬───────────────────────┘
                                        │
                                        ▼
                 ┌──────────────────────────────────────────────┐
                 │             Subcutaneous Lead                │
                 │   • Tunneled entirely extrathoracically      │
                 │   • Parasternal electrode alongside sternum  │
                 │   • Zero intravascular or cardiac entry      │
                 └──────────────────────┬───────────────────────┘
                                        │
         ┌──────────────────────────────┴──────────────────────────────┐
         ▼                                                             ▼
┌────────────────────────────────┐            ┌────────────────────────────────┐
│Advantages                      │            │Absolute Limitations            │
│• Preserves venous access       │            │• NO anti-tachycardia pacing    │
│• Eliminates tricuspid injury   │            │  (ATP) capability              │
│• No intravascular lead         │            │• NO bradycardia pacing support │
│• Simple surgical extraction    │            │• CANNOT deliver CRT pacing     │
│• Ideal for ESRD, hemodialysis  │            │• Requires pre-implant ECG test │
└────────────────────────────────┘            └────────────────────────────────┘

Clinical Evidence and Advantages

In the landmark PRAETORIAN trial, the S-ICD demonstrated non-inferiority to transvenous ICDs regarding device-related complications and inappropriate shocks. S-ICD is especially advantageous in:

• Younger patients with decades of device therapy ahead.
• Patients with compromised venous access, central venous occlusions, or indwelling hemodialysis catheters.
• Patients at high risk for systemic bacteremia or device infection (e.g., end-stage renal disease on hemodialysis, immunosuppressed post-transplant candidates).
• Patients with congenital heart disease or abnormal cardiac anatomy lacking transvenous access to the right ventricle.

Essential Pre-Implant Screening

Before S-ICD implantation, patients must undergo pre-implantation ECG vector screening in supine and standing positions across all three sensing vectors. The sensing algorithm must clearly differentiate the QRS complex from the T wave. Patients with excessive T-wave amplitude or wide, abnormal QRS-T morphology may fail screening due to the risk of T-wave oversensing, which could lead to inappropriate high-energy shocks.

Critical Clinical Limitations of S-ICD

The CHFN must recognize the three absolute clinical boundaries of the S-ICD system:

1. No Anti-Tachycardia Pacing (ATP): The S-ICD cannot deliver low-energy pacing bursts to painlessly terminate organized monomorphic VT. Every sustained VT or VF event requires a full high-energy shock (typically 80 Joules). Patients with recurrent monomorphic VT are poor candidates.
2. No Chronic Bradycardia Pacing: The S-ICD cannot pace for sinus node dysfunction or AV block. It provides only emergency transthoracic pacing for up to 30 seconds immediately following a defibrillation shock (at 50 bpm) and is incapable of long-term bradycardia pacing.
3. No Cardiac Resynchronization Therapy (CRT): Because the lead is subcutaneous and does not contact the myocardium, the S-ICD cannot deliver biventricular pacing for dyssynchrony. A patient with an indication for CRT must receive a transvenous CRT system.

---

CIED Selection Matrix at a Glance

---

Clinical Case Scenario: Biventricular Pacing Optimization

A 68-year-old male with non-ischemic cardiomyopathy and a CRT-D implanted 14 months ago presents to the outpatient heart failure clinic reporting worsening dyspnea on exertion (NYHA Class III) and 6 pounds of weight gain over the past three weeks. His current medications include sacubitril/valsartan 49/51 mg BID, carvedilol 25 mg BID, spironolactone 25 mg daily, empagliflozin 10 mg daily, and furosemide 40 mg daily.

• Vital Signs & Exam: BP 114/72 mmHg, HR 96 bpm (irregularly irregular), JVP 8 cm H₂O, bibasilar fine crackles, 1+ bilateral ankle edema.
• ECG: Atrial fibrillation with rapid ventricular response (ventricular rate 90–115 bpm) with intermittent narrow QRS complexes intermingled with wide paced complexes.
• Device Interrogation: Biventricular pacing percentage is 82% over the past 30 days (down from 99% six months ago). Episodes of paroxysmal atrial fibrillation have transitioned to permanent AFib with rapid ventricular conduction.
• Clinical Decision & Nursing Strategy:
  1. The nurse recognizes that the patient's clinical deterioration is directly driven by loss of biventricular capture (<98%) secondary to AFib with rapid ventricular response. Intrinsic AV conduction is suppressing biventricular pacing outputs, re-inducing mechanical dyssynchrony.
  2. Step 1 (Decongestion): Increase oral furosemide to 80 mg daily for 3 to 5 days to restore euvolemia.
  3. Step 2 (Rate Control): Initiate or uptitrate nodal blocking agents; however, carvedilol is already at 25 mg BID. Initiate oral amiodarone or digoxin to slow AV nodal conduction.
  4. Step 3 (Definitive Resynchronization Restoration): If pharmacological rate control fails to achieve >98% biventricular pacing consistently, refer the patient for catheter AV node ablation ("pace and ablate"). Ablating the AV junction permanently interrupts intrinsic fibrillatory conduction, allowing the CRT-D to pace the ventricles 100% of the time, thereby restoring mechanical synchrony and reverse remodeling.

---

CHFN Exam Traps & Clinical Pearls

[!WARNING] Exam Trap: Watch out for questions offering ICD implantation 2 weeks after an acute MI in a patient with an LVEF of 20%. Unless the patient has sustained unstable VT/VF outside 48 hours post-MI (secondary prevention), guidelines mandate a strict minimum 40-day waiting period post-MI before primary prevention ICD placement. Early implantation does not improve all-cause survival.

[!IMPORTANT] Clinical Pearl: Biventricular pacing percentage must exceed 98% to achieve clinical response and reverse ventricular remodeling. A pacing percentage of 92% is an abnormal finding that demands immediate clinical evaluation for AF with RVR, PVCs, or lead issues.

[!TIP] Clinical Pearl: The S-ICD does not deliver anti-tachycardia pacing (ATP) and does not provide bradycardia pacing. Never select an S-ICD for a patient with recurrent monomorphic VT (who needs ATP), symptomatic AV block (who needs bradycardia pacing), or LBBB with QRS ≥150 ms (who needs CRT).